Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction

This randomized controlled trial evaluated the safety, pharmacokinetics, and pharmacodynamics of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction (ED). The study found that PT-141 elicited significant erectile responses at doses greater than 7 mg, with erections occurring approximately 30 minutes post-administration. Pharmacokinetic